Uncovering the Role of DNA Repair Impairment in UVA‐Induced Mutagenesis in Human Xeroderma Pigmentosum Variant Cells
Molecular Carcinogenesis · 2025
DOI: 10.1002/mc.70028 ↗At a glance
Journal article in Molecular Carcinogenesis, 2025. Written by Camila Corradi and 7 co-authors. Institution: Laboratory of DNA Repair, Institute of Biomedical Sciences, University of São Paulo, São Paulo, SP, Brazil. Major MEDLINE topics: Ultraviolet Rays, DNA Repair, Xeroderma Pigmentosum, Mutagenesis. Cited 1 times so far (Crossref); 67 references. The full text is freely available (open access, CC BY 4.0). Funded by: This study was supported by the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES), Conselho Nacional de Desenvolvimento Científico e Tecnológ….
Abstract (original language)
Ultraviolet A (UVA) radiation induces DNA damage both directly, by forming cyclobutane pyrimidine dimers (CPDs), and indirectly, by generating oxidative stress. Cells rely on nucleotide excision repair (NER) and translesion synthesis (TLS) to tolerate these lesions. Xeroderma pigmentosum variant (XP‐V) cells, deficient in DNA polymerase eta (pol eta), exhibit a heightened risk of skin cancer due to impaired TLS. While XP‐V patients are considered NER‐proficient, our findings challenge this assumption by demonstrating that UVA‐induced oxidative stress impaired NER activity, leading to increased C > T transitions at CPD sites. Whole‐exome sequencing of UVA‐irradiated XP‐V cells revealed a substantial rise in mutations, with a distinct C > T signature characteristic of defective CPD repair. Notably, pretreatment with the antioxidant N ‐acetylcysteine (NAC) mitigated this effect, reducing C > T transitions through enhanced NER function and decreasing C > A transversions via its antioxidant properties. These results redefine the mutagenic landscape of XP‐V cells, revealing that oxidatively generated damage to NER proteins—rather than TLS deficiency alone—contributes to their elevated mutation burden. Our findings suggest that antioxidant strategies may partially protect XP‐V patients from UVA‐driven mutagenesis enhancing the cells' DNA repair capacity, ultimately reducing skin cancer and contributing to better overall health outcomes.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Laboratory of DNA Repair, Institute of Biomedical Sciences, University of São Paulo, São Paulo, SP, Brazil.
- Department of Cancer Biology, University of Kansas Medical Center, Kansas City, Kansas, USA.
- Faculty of Applied Science, Campinas University, Limeira, SP, Brazil.
- Laboratory of Genomic Integrity, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland, USA.
- TauGC Bioinformatics, São Paulo, SP, Brazil.
ORCID profiles: Camila Corradi, Marcela Teatin Latancia
Funding
- This study was supported by the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES), Conselho Nacional de Desenvolvimento Científico e Tecnológ…
Cite
APA
Corradi, C., Moreno, N. C., Quintero-Ruiz, N., Silva Leandro, G. D., Teatin Latancia, M., de Souza, T. A., Munford, V., & Menck, C. F. M. (2025). Uncovering the Role of DNA Repair Impairment in UVA‐Induced Mutagenesis in Human Xeroderma Pigmentosum Variant Cells. Molecular Carcinogenesis. https://doi.org/10.1002/mc.70028
Vancouver
Corradi C, Moreno NC, Quintero-Ruiz N, Silva Leandro GD, Teatin Latancia M, de Souza TA, et al. Uncovering the Role of DNA Repair Impairment in UVA‐Induced Mutagenesis in Human Xeroderma Pigmentosum Variant Cells. Molecular Carcinogenesis. 2025. doi:10.1002/mc.70028
BibTeX
@article{Corradi2025,
author = {Corradi, Camila and Moreno, Natália Cestari and Quintero-Ruiz, Nathalia and Silva Leandro, Giovana da and Teatin Latancia, Marcela and de Souza, Tiago Antonio and Munford, Veridiana and Menck, Carlos Frederico Martins},
title = {Uncovering the Role of DNA Repair Impairment in UVA‐Induced Mutagenesis in Human Xeroderma Pigmentosum Variant Cells},
journal = {Molecular Carcinogenesis},
year = {2025},
doi = {10.1002/mc.70028}
}
EUVIMED